Buy Skyrizi (risankizumab)

What is Skyrizi (risankizumab) for?

Buy Skyrizi (risankizumab). Skyrizi (risankizumab) is used to treat adults with:

• Plaque psoriasis that is moderate to severe in patients who are candidates for systemic therapy or phototherapy.
• Active psoriatic arthritis

It comes in a prefilled syringe and pen with 150 mg/mL of risankizumab.

How does Skyrizi (risankizumab) work?

The main ingredient in Skyrizi, risankizumab, is a human monoclonal antibody. It binds to interleukin (IL)-23 cytokines. Cytokines are important for cell signaling, especially in inflammation.

IL-23 is linked to diseases like psoriasis. By blocking IL-23, Skyrizi slows down inflammation.

Where has Skyrizi (risankizumab) been approved?

Skyrizi (risankizumab) has been approved by:

• The Food and Drug Administration (FDA), USA
  • On April 23, 2019 to treat moderate to severe plaque psoriasis.
  • On January 21, 2022 to treat active psoriatic arthritis.
• The European Medicines Agency (EMA)
  • On April 26, 2019 to treat moderate to severe plaque psoriasis.
  • On November 22, 2021 to treat active psoriatic arthritis.
• Therapeutic Goods Administration (TGA)
  • On July 23, 2019 to treat moderate to severe plaque psoriasis.

This medicine may also be approved in other regions. If you have questions, contact our support team. /contact-us

How is Skyrizi (risankizumab) taken?

The standard dosage is:

• The first two doses of 150 mg are given 4 weeks apart
• The following doses are given every 12 weeks

Skyrizi is injected under the skin (subcutaneous).

You can get it in a treatment center or at home after training from your doctor.

For more details on dosage and administration, see the official prescribing information in our references section.

Note: Please consult with your treating doctor for personalized dosing.

Are there any known adverse reactions or side effects of Skyrizi (risankizumab)?

Common adverse reactions

The most common side effects (≥1% of patients) include:

• Upper respiratory infections
• Headache
• Fatigue
• Injection site reactions
• Tinea infections

Serious adverse reactions

The serious adverse reactions include:

• Hypersensitivity reaction
• Infections
• Tuberculosis (TB)

Use in a specific population

Skyrizi (risankizumab) may harm your unborn baby if you’re pregnant. It can also affect fertility in both males and females. Talk to your healthcare provider if you’re concerned.

For a full list of side effects and adverse reactions, see the official prescribing information.

Buy Rinvoq (upadacitinib)